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ABSTRACT
OBJECTIVE: The objective of this selective Evidence Based Medicine (EBM) review is to
determine whether or not “Are psychedelics effective in treating anxiety associated with a lifethreatening disease?”
STUDY DESIGN: Review of two double-blind, randomized, placebo-controlled pilot studies
and one randomized controlled trial (RCT).
DATA SOURCES: All studies were published in peer-reviewed journals found via the use of
PubMed Database.
OUTCOMES MEASURED: The outcome measured in this EBM was the effect of psilocybin or
LSD on the reduction in anxiety. Reduction in anxiety was measured using either the Hamilton
Anxiety Rating Scale (HAM-A) or the State-Trait Anxiety Inventory (STAI). Participants
subjectively rated their anxiety pre- and post-drug administration.
RESULTS: The results of each study reached statistical significance, indicating psilocybin or
LSD to be an effective form of treatment for anxiety in patients with a life-threatening disease.
The study by Gasser et al. showed a significant reduction in state anxiety from baseline to 2
months post-LSD administration (p = 0.021). Grob et al. showed a significant decrease in trait
anxiety at the 1-month (p = 0.001) and 3-month (p = 0.03) follow-ups after psilocybin
administration. Lastly, Griffiths et al. found that 76% of patients administered high-dose
psilocybin had a >50% reduction in their anxiety 5 weeks after treatment as compared to 24% of
those participants in the control group, with a number needed to treat (NNT) of 2.
CONCLUSION: Both pilot studies and the RCT included in this review indicate that LSD or
psilocybin are an effective treatment for anxiety associated with a life-threatening disease.
KEY WORDS: Psilocybin, Lysergic Acid Diethylamide, Anxiety
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INTRODUCTION
Anxiety is among the most prevalent mental health disorders in the United States. It is an
expected, normal, and transient response to stress; however, anxiety is pathologic when it has no
identifiable internal or external trigger, exceeds a patient’s capacity to bear discomfort, the
symptoms are persistent, and it results in avoidance and/or withdrawal behaviors. Anxiety is
characterized by persistent feelings of apprehension and excessive worry, and can be
accompanied by somatic symptoms (e.g. palpitations, chest tightness, lightheadedness,
restlessness). It also has the ability to alter one’s cognitive and affective functioning.
Anxiety disorders are the most common mental illness in the United States.
Approximately 40 million people older than the age of 18 are affected. Individuals with a life1

threatening disease, such as pancreatic cancer or Parkinson’s disease, are especially vulnerable to
developing anxiety. It is estimated that 2-14% of terminally ill patients suffer from anxiety
disorders, with generalized anxiety disorder (GAD) and panic disorder being the most common
manifestations. Roughly 25-48% of patients exclusively with cancer experience both
2

psychological and physical anxiety-related symptoms. Not only is the prevalence of anxiety
2

high, but so too is the cost. In the U.S., anxiety disorders have been estimated to cost between
$42.3 and $46.6 billion annually. The mean total medical cost for a patient diagnosed with an
3

anxiety disorder is $6,475. An estimated total of $18.4 billion has been spent on prescription
3

medications for those individuals diagnosed with anxiety or a mood disorder. It is also one of the
4

most common reasons for psychiatric consultation among those patients suffering from fatal
illness. No recent estimates have been made on the number of annual visits made for anxiety;
2

however, a study published in 2002 noted an increase from 9.5 million visits in 1985 to 12.3
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million visits in 1997-1998, indicating a rising trend in the number of healthcare visits scheduled
for anxiety-related conditions.

5

Anxiety is thought to arise from an unknown internal stimulus or is an inappropriate or
excessive response when compared to an external stimulus. The cause of anxiety is multifactorial, involving environmental, social, and biological factors. Several environmental and
social factors can predispose one to anxiety. For instance, more recent stressful life events,
especially those characterized by illness and death, increase the risk of anxiety and depression. In
6

patients with a known medical illness, the condition, its complications, and the treatment of the
illness are all suspected to be causes of anxiety. Biologically, both the hippocampus and
activation of the amygdala are also noted to have a role in the development of anxiety.
Connections between the amygdala and pre-frontal cortex are responsible for the conscious
experience and regulation of emotion. Brain imaging studies have demonstrated that individuals
6

with anxiety show amplified responses in these areas of the brain when confronted with an
emotionally intimidating stimulus. This indicates that individuals with anxiety may have a preexisting abnormality in the neural connection between the pre-frontal cortex and amygdala that
predisposes them to anxiety disorders. Many neurotransmitters also generate and modulate
6

anxiety symptoms, including norepinephrine, serotonin, dopamine, and GABA.
Many treatments are available to control episodes of anxiety as well as exacerbations of
anxiety. Most commonly used at the selective serotonin reuptake inhibitors (SSRIs), such as
paroxetine (Paxil), fluoxetine (Prozac), sertraline (Zoloft), citalopram (Celexa), and escitalopram
(Lexapro). These medications block the reuptake of serotonin at pre-synaptic receptors. Second
line medications that have been used are serotonin-norepinephrine (NE) reuptake inhibitors
(SNRIs). These medications include duloxetine (Cymbalta) and venlafaxine (Effexor), and are
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similar to SSRIs, but also block the reuptake of NE and dopamine. Benzodiazepines are
indicated for short-term use in the management of anxiety. These medications include,
lorazepam (Ativan), alprazolam (Xanax), and diazepam (Valium). The treatment options
described above are effective in treating anxiety. However, each class of medication has
demonstrated various gastrointestinal and cardiac side effects (e.g. hypertension) in different
types of people. Cancer patients, specifically, fail to achieve satisfactory relief from the available
medications previously listed. Without appropriate treatment, anxiety persists as a serious
problem for these people. This population thus warrants the need for more effective
interventions. Psilocybin and LSD are potential alternatives that may be effective in the
treatment of anxiety associated with cancer. This paper evaluates two double-blind, randomized,
placebo-controlled pilot studies and 1 randomized control trial (RCT) surveying the effects of
psychedelics, specifically psilocybin or lysergic acid diethylamide (LSD), in the treatment of
anxiety related to a life-threatening disease.
OBJECTIVE
The objective of this selective Evidence Based Medicine (EBM) review is to determine
whether or not “Are psychedelics effective in treating anxiety associated with a life-threatening
disease?”
METHODS
This investigation looks at two double-blind, randomized, placebo-controlled pilot
studies and one randomized controlled trial (RCT). The population of the studies used for this
review includes both men and women diagnosed with a life-threatening disease as well as a
DSM-IV anxiety disorder diagnosis. Participants across all studies were older than 35 years of
age. All studies used a psychedelic, either LSD or psilocybin, as the intervention and an active
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placebo. Active placebos were chosen in order to produce mild and detectable effects of the
drugs, but were not substantial enough to produce any therapeutic effects. The purpose of the
active placebo is to aid in the blinding of the study. In Gasser et al., the intervention addressed
was LSD. LSD was administered orally as capsules consisting of 200 μg. The subjects acted as
their own control. The comparison group consisted of an active placebo of 20 μg of LSD. In
Grob et al., the intervention addressed was psilocybin. Subjects were administered active
psilocybin (0.2 mg/kg). The placebo was niacin (250 mg). Griffiths et al. utilized psilocybin as
8

the therapeutic intervention. High dose psilocybin (22 or 30 mg/70 kg) was administered orally
in opaque, size 0 gelatin capsules with lactose as the capsule filler. A placebo-like low dose of
psilocybin (1 or 3 mg/70 kg) was utilized as the comparison group. The main outcome measured
9

was a reduction in anxiety as demonstrated by either the State-Trait Anxiety Inventory (STAI) or
the Hamilton Anxiety Rating Scale (HAM-A).
The author, using the key words “lysergic diethylamide acid,” “psilocybin,” and
“anxiety,” carried out a detailed search using the Cochrane Systematic Review and PubMed. All
studies were published in English in peer-reviewed journals. All studies were published after the
year of 2010 and were selected based on their relevance to the topic and whether or not they
included patient oriented evidence that matters (POEMs). Inclusion criteria for this systematic
review randomized controlled trials. Exclusion criteria included previous Cochrane reviews as
well as systematic reviews submitted by previous students. Inclusion and exclusion for the
individual studies are included in Table 1. The statistics of this study used to evaluate patient
outcomes included t-value, p-value, F-score, RBI, ABI, NNT. All studies used similar statistics
to evaluate the outcomes where p-value is considered statistically significant if it is < 0.05 or <
0.025 (two-tailed). The demographics of the studies are included and outlined in Table 1.
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Table 1: Demographics & Characteristics of Included Studies
Study

Type

Number
of
Patients
12

Gasser, et
al. (2014)

double-blind,
randomized,
placebocontrolled
pilot study

Grob, et
al. (2011)

double-blind,
randomized,
placebocontrolled
pilot study

12

randomized
controlled
trial

56

7

8

Griffiths,
et al.
(2016)
9

Age
(years)
39-64
y/o

36-58
y/o

mean
age of
56 y/o

Inclusion Criteria

Exclusion criteria

patients w/ a lifethreatening disease
with a score greater
than 40 on either the
state or trait scale
on the Spielberger
State-Trait Anxiety
Inventory
advanced-stage
cancer and a DSMIV diagnosis of
acute stress
disorder,
generalized anxiety
disorder, anxiety
disorder due to
cancer, or
adjustment disorder
with anxiety

current alcohol or drug
dependence; bipolar I,
dissociative disorders;
neurocognitive impairment;
women pregnant or nursing

2

lysergic
diethylamide
acid (200 μg)
in capsules

CNS involvement of the
cancer, severe
cardiovascular illness,
untreated HTN, abnormal
hepatic or renal function,
DM, life-time history of
schizophrenia, bipolar
disease, anxiety or affective
disorders within 1 year
prior to the onset of the
cancer, active cancer
chemotherapy, antiseizure
medications,
insulin/hypoglycemic
medications, or
psychotropic medications 2
weeks prior to treatment
CNS involvement of
cancer, hepatic dysfunction,
paraneoplastic syndrome,
uncontrolled HTN, angina,
EKG abnormality, stroke,
epilepsy, renal
insufficiency, DM1,
pregnant females

4

psilocybin (0.2
mg/kg) with
100 mL of H O
in clear 00
capsules with
corn starch

life-threatening
cancer diagnosis
and a DSM-IV
diagnosis that
included chronic
adjustment disorder
with anxiety,
chronic adjustment
disorder with mixed
anxiety and
depressed mood,
dysthymic disorder,
generalized anxiety
disorder, or major
depressive disorder

W/D

Interventions

2

10

psilocybin (22
or 30 mg/70
kg)
administered in
opaque, size 0
gelatin capsules
with lactose as
the capsule
filler

OUTCOMES MEASURED
The main outcome measured in the selected studies is the effectiveness of psychedelics,
specifically LSD and psilocybin, in the reduction of anxiety associated with a life-threatening
disease. Gasser et al. and Grob et al. utilized the State-Trait Anxiety Inventory (STAI).

7,8

Participants subjectively rated their anxiety pre- and post-drug administration. The STAI
measures anxiety by assessing feelings of apprehension, tension, nervousness, and worry. The
8
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STAI measures state and trait anxiety separately. State anxiety refers to a temporary state of
anxiety. The state anxiety subscale of the STAI gears its questions towards the patient’s present
feelings of anxiety. Trait anxiety refers to long-standing and enduring feelings of anxiety. The
trait anxiety subscale assesses the patient’s overall view of him or herself as a person. The STAI
has 20 items for assessing trait anxiety and 20 items for state anxiety. All items are rated on a 4point scale (e.g., from “Almost Never” to “Almost Always”). Higher scores indicate greater
anxiety.
Griffiths et al. utilized the Hamilton Anxiety Rating Scale (HAM-A). HAM-A is a
clinician-rated scale that consists of 14 items (anxious mood, tension, fears, insomnia,
intellectual depressed mood, somatic (muscular) symptoms, somatic (sensory) symptoms,
cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary
symptoms, autonomic symptoms, and behavior during the interview). Each item is graded on a
scale from 0 to 4. The HAM-A score can range from 0 to 56. A score < 17 is indicative of mild
anxiety, 18-24 indicates mild to moderate anxiety, and 25-30 indicates moderate to severe
anxiety.
RESULTS
Gasser et al. conducted a pilot study that was 12 months in duration. Subjects were
randomly assigned to an experimental or comparison group. Those in the experimental group (n
= 8) received 200 μg of LSD. Those in the comparison group were administered 20 μg (n = 4) of
LSD. This dose of LSD was chosen to produce mild and detectable effects of LSD, but were not
substantial enough to produce any therapeutic effects. The purpose of using LSD as an active
placebo was to produce noticeable effects to convince the subject that he/she was receiving the
legitimate treatment. All subjects were blinded to the condition assignment. LSD was
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administered to the subjects at two separate times, 2-3 weeks apart, in the setting of a quiet and
safe private practice office. The STAI was administered to the subjects prior to treatment, after
each experimental session, and then again at a 2-month follow-up. After the 2-month follow-up,
the conditions were revealed to the subjects. Those subjects that received the placebo were
offered the opportunity to crossover to receive the active intervention; however, this was not
blinded. All subjects, including those that participated in the open-label crossover, were required
to complete a 12-month follow-up of the STAI. At the conclusion of the 2-month follow-up, all
subjects that entered the trial were accounted for; however, at the 12-month follow-up after the
open-label crossover, only 6 of the 8 subjects in the original experimental group completed the
12-month follow-up evaluation (1 subject died due to cancer, 1 subject did not complete the
evaluation). One subject from the active placebo group was not analyzed due to the development
of exclusion criteria. Therefore, only 3 subjects from the active placebo completed the open-label
crossover. Those 3 subjects participated in the 12-month follow-up evaluation. Thus, only 9 total
subjects completed the 12-month follow-up.
The effect of LSD on anxiety was measured utilizing the STAI. Analysis of variance
(ANOVA) was used to assess for significant changes in anxiety from baseline to post-LSD
administration. State and trait anxiety were analyzed separately. Significance was demonstrated
by p < 0.025 (two-tailed). Prior to treatment, no significant difference was found in the mean
STAI-Trait scores (p = 0.261) or STAI-State scores (p = 0.563) between the groups at baseline.
There was no significant difference in trait anxiety from baseline to 2 months post-LSD
administration in the experimental group (F(2,18) = 4.151, p = 0.033). Those subjects receiving
the active placebo experienced increased trait anxiety, but this was not found to be statistically
significant. There was a significant difference in state anxiety from baseline to 2 months post-
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LSD administration in the experimental group (F(2,18) = 4.846, p = 0.021), see Table 2. The Fscore is higher than its respective F-critical value, indicating that LSD was effective in reducing
state anxiety 2 months after drug administration. The p-value indicates that this effect is
significant (p < 0.025). Those individuals receiving the active placebo experienced an elevation
in state anxiety, but again, this was not found to be statistically significant. At the 12-month
follow-up after the open-label crossover, the mean difference between state anxiety at 2 months
and state anxiety at 12 months was 1.0 (p = 0.531). This indicates there was no significant
change in state anxiety from 2 months to 12 months, indicating that the effect of LSD in reducing
state anxiety was maintained over time.
Table 2. Mean Change in STAI-State or STAI-Trait Anxiety as Measured by Gasser et al. 2014
STAI-Trait
STAI-State
*p = 0.021

Baseline
Experimental Placebo
53.2
43.3
53.1
47.7

2-Month Follow-Up
Experimental Placebo
45.2
49.0
41.5*
51.7

12-Month Follow-Up
All
41.1
36.1

Grob et al. conducted a pilot study that was 6 months in duration. Subjects participated in
two experimental sessions that took place several weeks apart. Subjects acted as his/her own
control, and were informed that they would receive 0.2 mg/kg of psilocybin during one session
and 200 mg of niacin during the other session; however, the order in which the subjects received
those treatments was randomized. The STAI was administered to and completed by participants
1 day prior to treatment, 6 hours after treatment, 1 day after treatment, and 2 weeks after
treatment. The STAI was then also administered at monthly intervals for 6 months following the
study. A t-test was used to compare the STAI at baseline to the STAI values 1, 2, 3, 4, 5, and 6
months following psilocybin treatment. The t-test determines if the 2 groups being compared
(pre-psilocybin administration and post-psilocybin administration) differ significantly. The tvalue is compared to a critical value. If the intervention in question has an effect, the t-value will
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be greater than the critical value. The significance of this effect is then determined by a p-value.
In this study, p < 0.05 was considered clinically significant. At the conclusion of the 3-month
follow-up, all subjects that entered the trial were accounted for; however, only 8 of the 12
subjects completed the 6-month follow-up STAI (2 participants died and 2 were too sick to
continue participating).
The numerical values of the STAI mean scores, as well as the mean change from
baseline, were not presented within the article. Data were presented graphically. The STAI did
not show any significant changes in state or trait anxiety from baseline to 2 weeks after
psilocybin administration. There was a decrease in state anxiety 6 h following psilocybin
administration, but it was not found to be clinically significant. There were no significant
findings of the effect of psilocybin on state anxiety for follow-up. However, there was a decrease
in trait anxiety at the 1-month follow-up (t = 4.36, p = 0.001) and 3-month follow-up (t = 2.55,
11

10

p = 0.03). The t-scores indicate that the psilocybin had an effect on STAI trait anxiety 1 and 3
months following treatment. The t-scores from the 1- and 3-month follow-ups are higher than
their respective critical t-values. Therefore, the large t-scores demonstrate that psilocybin had a
large effect in reducing trait anxiety 1 and 3 months following psilocybin administration.
Psilocybin’s effect was large, and the p-values indicate that its effect in reducing trait anxiety is
significant (p < 0.05).
Griffiths et al. conducted a RCT that was 6 months in duration. The subjects acted as
9

their own controls. Subjects were told they would be receiving psilocybin, but the order of
administration of the treatments was randomized. In this study, a low dose and high dose of
psilocybin was used. Subjects in the comparison group were administered a placebo-like low
dose of psilocybin (1 or 3 mg/70 kg). The low dose was decreased from 3 to 1 mg/70 kg after

Wilwohl, Psychedelics & Anxiety 10
concern that the 3 mg/70 kg dose may show significant therapeutic effects, and thus would not
be an inactive placebo. Subjects in the experimental group were administered 22 or 30 mg/70 kg.
The high dose was decreased from 30 to 22 mg/70 kg after 2 of the first 3 participants that
received the 30 mg/70 kg dose of psilocybin were removed from the study (1 subject vomited
shortly after capsule administration and 1 left due to personal reasons). The study also indicated
that psychologically challenging experiences were more likely to occur with a 30 mg/70 kg dose
of psilocybin.
A clinical response to the psilocybin was defined as a >50% decrease in the HAM-A
score relative to baseline. Five weeks after the first session and prior to crossover, there was a
significant difference between subjects in the High-Dose-1 group compared to subjects in the
st

Low-Dose-1 group. Significance was indicated by p < 0.001. Approximately 76% of patients
st

administered the high-dose psilocybin (22 or 30 mg/70 kg) had a >50% reduction in their anxiety
5 weeks after treatment as compared to 24% of those participants receiving the low-dose
psilocybin. The NNT was calculated to be 2 (see Table 3). This positive number indicates that
two patients are needed to treat in order for one patient to have a ≥50% decrease in their anxiety
(as measured with the HAM-A score) compared to the placebo.
Table 3: Efficacy of Psilocybin in the Treatment of Anxiety Associated with a Life-Threatening
Disease as Measured by Griffiths et al. 2016
Study

Control
Event Rate
(CER)

Experiment
Event Rate
(EER)

Relative Benefit
Increase (RBI)

Absolute Benefit
Increase (ABI)

Number
Needed to
Treat (NNT)

p-value

Griffiths et
al. (2016)

0.24

0.76

2.2

0.52

2

< 0.001

DISCUSSION
The three RCTs analyzed in this systematic review demonstrated a significant reduction
in state or trait anxiety through the administration of either LSD or psilocybin. Lysergic acid
7,8,9

diethylamide is a semisynthetic compound that produces many psychosensory changes, such as
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increased sensory perception and hallucinations, when administered in large doses. It exhibits its
psychedelic effects through the activation of 5-HT receptors. Psilocybin is a natural
7

2A

hallucinogen found in various types of mushrooms. It is a 5-HT receptor agonist that, when
2A

administered in larger doses, produces fluctuations in thoughts, perceptions, and emotions.

8,9

There are no current uses for psilocybin and LSD in medicine today. They are considered “street
drugs” used primarily for the purpose of experiencing euphoria. Both drugs are frequently
associated with triggering panic attacks or feelings of extreme anxiety when used in excess.
However, in a controlled environment, when LSD and psilocybin are administered at higher
doses, it is thought that they induce moments of catharsis. These drugs are capable of provoking
7

powerful spiritual experiences, during which users feel they have come in contact with a greater
existence and sense of liberation. It is these psychosensory effects of LSD and psilocybin that
7,8,9

enable those with anxiety to persevere through the mental and emotional burden that they carry.
Therefore, by establishing an appropriate treatment protocol and therapeutic window of both
LSD and psilocybin, these drugs can serve as effective anxiolytics, especially in those patients
with a terminal disease.
Both LSD and psilocybin are not currently approved for use in medicine by the FDA.
Furthermore, they are on the illicit market and are illegal in the U.S. due to their high potential
for abuse and side effect profile. However, psychedelic properties of these drugs in a controlled
setting may play a role in the reduction of anxiety. Serotonin deficiency is a proposed causal
theory of anxiety. LSD and psilocybin exhibit their psychedelic effects through the activation of
6

5-HT receptors. In activating 5-HT receptors, these drugs may also stimulate the release of
2A

7,8,9

2A

more serotonin, thus replenishing the serotonin that is lacking in those individuals with anxiety.
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It is important to acknowledge the limitations that exist across each of the studies.
Although the participants were kept blind, when administering a hallucinogenic drug like
psilocybin or LSD, the blinding of each of the studies was challenged. Psilocybin and LSD,
when compared to the alternative placebo, produced discriminable effects; therefore, the order in
which the drugs were administered was made apparent to some of the subjects. Across all
studies, a strict exclusion criteria were also used, resulting in a small sample size. A small
sample size reduces the precision of statistics and does not adequately reflect an entire
population. The population addressed is also a challenging population due to their advancedstage cancer diagnoses. When advanced, cancer has the potential to alter the patients’ physical
and mental states, thus potentially altering the patients’ overall interpretations of the therapy.
CONCLUSION
Psilocybin and LSD are effective alternatives for the treatment of anxiety associated with
a life-threatening disease. The randomized controlled trials analyzed in this systematic review
showed significant reduction in anxiety after the administration of psilocybin or LSD. Although
not specifically addressed in this systematic review, psychotherapy in addition to the use of
psychedelics yields the most effective treatment for anxiety.

7,8,9

Despite the promising results presented within each of these articles, further research is
warranted to draw conclusions regarding the best treatment protocol. Given the hallucinogenic
properties of these drugs, it is important to establish a therapeutic window that proves most
beneficial without eliciting undesired psychical and psychological side effects, such as tremors,
hyperglycemia, hyperreflexia, visual hallucinations, suicidal ideations, etc. The populations
enrolled in each of the studies were substantially limited due to a strict inclusion/exclusion
criteria. Future studies should aim to broaden the inclusion/exclusion criteria to include a wider
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and more generalized population of individuals affected by anxiety. By enrolling a wider range
of subjects, psychedelics will not only be used for anxiety associated with a terminal disease, but
are also likely to be utilized for the treatment of anxiety in the generalized population.
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